Trial Profile

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemetrexed (Primary)
Indications Adenocarcinoma; Brain metastases; Lung cancer
Focus Therapeutic Use

Most Recent Events

01 Aug 2017 Status changed from not yet recruiting to recruiting as per the results published in the Anticancer Research.
01 Aug 2017 Results (n=60; data cut off Oct 2015) assessing efficacy and safety published in the Anticancer Research.
11 Nov 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com